{"prompt": "['Product: MK-3475', '13', 'Protocol/Amendment No.: 604-09', 'SUMMARY OF CHANGES', 'PRIMARY REASON(S) FOR THIS AMENDMENT:', 'Section Number', 'Section Title', 'Description of Change(s)', 'Rationale', '8.7', 'Interim Analyses', 'The final analysis timing was updated as', 'By allowing the final os analysis to occur', 'follows: \"The final os analysis is planned', 'after a minimum of 294 events have been', 'when a minimum of 294 deaths have been', 'observed or approximately 31 months after', 'observed or approximately 31 months after', 'the first subject is enrolled, whichever', 'first subject enrolled, whichever occurs', 'occurs later, the trial ensures adequate', \"later.'\", 'follow-up time for the final OS analysis.', '8.8', 'Multiplicity', 'Added the following statements to describe', 'To clarify that the alpha spending is event', 'the alpha-spending strategy for PFS and', 'based, and not subjected to change, if the', 'os in detail: \"The alpha spending at each', 'actual number of events at the final', 'interim analysis is determined using a Lan-', 'analysis exceeds the targeted number of', \"DeMets O'Brien-Fleming spending\", 'events at final analysis.', 'function, and the information fraction', '(ratio of the actual number of events at the', 'interim analysis relative to a targeted 294', 'events at the final analysis). The final', 'analysis will use the remaining Type I', 'error not spent at earlier analyses,', 'regardless of the number of events', 'observed at the final analysis. The p-value', 'bounds at second interim and final analysis', 'will be calculated by considering the', 'correlation between the test statistics as', 'determined by the actual number of os', 'events at the previous and current', 'analysis.\"', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '14', 'Protocol/Amendment No.: 604-09', 'ADDITIONAL CHANGE(S) FOR THIS AMENDMENT:', 'Section Number', 'Section Title', 'Description of Change(s)', 'Rationale', '11.0', 'List of References', 'Included all references cited in', 'Due to a publishing error, the list of references in', 'the text of the protocol.', 'protocol Section 11.0 was truncated when Amendment', '08 was finalized. Therefore, it is being updated here.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '15', 'Protocol/Amendment No.: 604-09', '1.0 TRIAL SUMMARY', 'Abbreviated Title', 'Phase 3 trial of first line etoposide/platinum (EP) with or without', 'pembrolizumab in ES-SCLC (KEYNOTE-604)', 'Sponsor Product Identifiers', 'MK-3475', 'Pembrolizumab', 'Trial Phase', 'III', 'Clinical Indication', 'First-line treatment of extensive stage small cell lung cancer', '(ES-SCLC) in combination with standard of care (SOC)', 'chemotherapy', 'Trial Type', 'Interventional', 'Type of control', 'Placebo', 'Route of administration', 'Intravenous (IV)', 'Trial Blinding', 'Double-blind', 'Treatment Groups', 'Arm 1: Pembrolizumab + EP:', 'Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1', 'Etoposide 100 mg/m\u00b2 IV Q3W on Days 1, 2, and 3', \"Platinum, investigator's choice\", 'Carboplatin titrated to an area under the plasma drug', 'concentration-time curve (AUC) of 5 IV Q3W on Day 1', 'OR', 'Cisplatin 75 mg/m\u00b2 IV Q3W on Day 1', 'Arm 2: Placebo + EP:', 'Placebo IV Q3W on Day 1', 'Etoposide 100 mg/m\u00b2 IV Q3W on Days 1, 2, and 3', \"Platinum, investigator's choice\", 'Carboplatin titrated to an AUC of 5 IV Q3W on Day 1', 'OR', 'Cisplatin 75 mg/m\u00b2 IV Q3W on Day 1', 'Number of trial subjects', 'Approximately 430 subjects will be enrolled.', 'Estimated duration of trial', 'The Sponsor estimates that the trial will require approximately', '4.5 years from the time the first subject signs the informed consent', \"until the last subject's last study-related phone call or visit.\", 'Duration of Participation', 'Each subject will participate in the trial from the time the subject', 'signs the informed consent form through the final protocol-specified', 'contact.', 'After a screening phase of up to 28 days, each subject will be', 'randomized to receive trial treatment (pembrolizumab + EP or', 'placebo + EP). The SOC treatment component (EP) will be given', 'for the first 4 cycles with pembrolizumab or placebo, after which', 'partial and complete responders may receive prophylactic cranial', 'irradiation at the discretion of the investigator. Treatment with', 'pembrolizumab or placebo will continue until a total of 35 cycles of', 'treatment have been administered or until one of the treatment', 'discontinuation criteria occurs: confirmed disease progression,', 'unacceptable adverse event(s) (AEs), intercurrent illness,', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}